NDA 207356 · Insmed INC
Arikayce Kit
Amikacin Sulfate · Inhalation · Aminoglycoside Antibacterial
Breakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 28, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
104
24 Phase 3, 13 recruiting
FAERS reports
17,297
14,295 serious, 3,446 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS ARIKAYCE has been associated with an increased risk of respiratory adverse reactions including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases [see Warnings and Precautions (5.1 , 5.2 , 5.3 , 5.4) ] . WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS See full prescribing information for complete boxed warning. ARIKAYCE has been associated with a risk of increased respiratory adverse reactions, including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases. ( 5.1 , 5.2 , 5.3 , 5.4 )
What it is approved for
From the label in effect Aug 4, 2026.
LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options . This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials . LIMITED POPULATION: ARIKAYCE is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. ( 1 ) This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3...
Mechanism: ARIKAYCE is an antibacterial drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 19, 2020 Supplement 3 · Efficacy OrphanLetterLabel
- Sep 28, 2018 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- ARIKAYCE KIT · AMIKACIN SULFATE EQ 590MG BASE/8.4ML · SUSPENSION, LIPOSOMAL, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amikacin" as an intervention, any sponsor and status, largest first.
- Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated PneumoniaPivotal-lookingCompleted
University Hospital, ToursAcademic, hospital or other
NCT03149640 · 850 participants · Start Jul 19, 2017 · Primary completion Mar 9, 2021
Drug: Inhaled amikacin; Inhaled placebo · For: Pneumonia, Ventilator-Associated
Sites: Angers, France; Angoulême, France; Argenteuil, France · 18 sites in all
- Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative PneumoniaPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01799993 · 725 participants · Start Apr 13, 2013 · Primary completion Apr 7, 2017
Drug: Amikacin Inhalation Solution (BAY41-6551); Aerosolized Placebo · For: Pneumonia, Bacterial
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 65 sites in all
Northwestern UniversityAcademic, hospital or other
NCT01659866 · 563 participants · Start Aug 2012 · Primary completion Aug 2015
Drug: Ciprofloxacin; trimethoprim-sulfamethoxazole and 11 more · For: Infection
Sites: Chicago, Illinois
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of CarePivotal-lookingRecruiting
Uppsala UniversityAcademic, hospital or other
NCT07236944 · 560 participants (planned) · Start Dec 2025 · Primary completion Mar 2029
Drug: Pivmecillinam; Standard of Care (Investigator Choice) · For: Febrile Urinary Tract Infection
Sites: Haukeland, Norway; Oslo, Norway; Borås, Sweden · 13 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000796 · 525 participants
Drug: Cycloserine; Ethionamide and 11 more · For: HIV Infections; Tuberculosis
Sites: Chicago, Illinois; Detroit, Michigan; Brooklyn, New York · 21 sites in all
- The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TBCompleted
Beijing Chest HospitalAcademic, hospital or other
NCT03830671 · 515 participants · Start Mar 8, 2019 · Primary completion Jun 8, 2022
Drug: 18-month regimen containing 6 anti-TB drugs · For: Multi-drug Resistant Tuberculosis
Sites: Beijing, China; Changchun, China; Changsha, China · 20 sites in all
- NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TBPivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT03604848 · 488 participants (planned) · Start Aug 5, 2018 · Primary completion Aug 4, 2024
Drug: WHO-approved MDR-TB regimen; NGS-guided regimen: Regimen A and 2 more · For: Multidrug Resistant Tuberculosis
Sites: Shenzhen, China; Harbin, China; Zhengzhou, China · 12 sites in all
- 3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in ChildrenPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT05544565 · 480 participants (planned) · Start Mar 22, 2023 · Primary completion Jan 2028
Drug: IV Antibacterial Agents; Orally antibacterial agents · For: Pyelonephritis Acute
Sites: Corbeil-Essonnes, France; Orsay, France; Clamart, France · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,052
- drug ineffective1,836
- cough1,733
- dyspnoea1,666
- therapy interrupted1,437
- hospitalisation1,415
- death1,154
- dysphonia1,046
- nausea800
- product dose omission issue786
- fatigue781
- pneumonia703
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 137 |
| 2005 | 104 |
| 2006 | 98 |
| 2007 | 134 |
| 2008 | 136 |
| 2009 | 120 |
| 2010 | 146 |
| 2011 | 230 |
| 2012 | 212 |
| 2013 | 220 |
| 2014 | 209 |
| 2015 | 275 |
| 2016 | 408 |
| 2017 | 508 |
| 2018 | 811 |
| 2019 | 2,136 |
| 2020 | 1,812 |
| 2021 | 1,453 |
| 2022 | 1,387 |
| 2023 | 1,869 |
| 2024 | 2,088 |
| 2025 | 1,781 |
| 2026 | 1,023 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.
Schwab TC, Perrig L, Göller PC, et al. · Lancet Infect Dis 2024 · Systematic Review, Meta-Analysis
- Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Ehrmann S, Barbier F, Demiselle J, et al. · N Engl J Med 2023 · Equivalence Trial, Multicenter Study
- Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L, Righi E, Chiamenti M, et al. · Int J Antimicrob Agents 2021 · Systematic Review, Network Meta-Analysis
- Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, et al. · Am J Respir Crit Care Med 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, et al. · Lancet Respir Med 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.
· Arch Ophthalmol 1995 · Clinical Trial, Multicenter Study
Sponsor: Insmed INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.